Literature DB >> 26622774

PU.1 affects proliferation of the human acute myeloid leukemia U937 cell line by directly regulating MEIS1.

Jing Zhou1, Xiaofeng Zhang2, Yuhua Wang3, Yinghui Guan4.   

Abstract

The transcription factor PU.1 is a member of the ETS family, which is expressed in a wide variety of hematopoietic lineages. Accumulating evidence has indicated that PU.1 plays a key role in hematopoiesis, and reduced expression of PU.1 leads to the pathogenesis of human myeloid leukemia. As a multi-functional factor, PU.1 is also required for mixed lineage leukemia (MLL) stem cell potential and the development of MLL. However, the function of PU.1 in human non-MLL leukemia and its molecular mechanism remains poorly understood. In the present study, PU.1 siRNA was demonstrated to efficiently inhibit the transcription level of oncogene MEIS1 in the human acute myeloid non-MLL leukemia U937 cell line. In addition, PU.1, as a positive regulator of MEIS1, performed a crucial role in maintaining cell proliferation. Using electrophoretic mobility shift assay, chromatin immunoprecipitation analysis and luciferase reporter assay, previously unexplored evidence that PU.1 activated the MEIS1 promoter through a conserved binding motif in vitro and in vivo was further defined. Overall, the present study provides insight into the molecular mechanism of the contribution of PU.1 to the pathogenesis of non-MLL U937 cells, which is mediated by direct regulation of MEIS1 transcription. The present data reveal the possibility of developing an alternative therapy for non-MLL leukemia by targeting PU.1-mediated MEIS1 gene activation.

Entities:  

Keywords:  MEIS1; PU.1; leukemia; transcription

Year:  2015        PMID: 26622774      PMCID: PMC4533722          DOI: 10.3892/ol.2015.3404

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  28 in total

1.  Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation.

Authors:  Kira Orlovsky; Alexander Kalinkovich; Tanya Rozovskaia; Elias Shezen; Tomer Itkin; Hansjuerg Alder; Hatice Gulcin Ozer; Letizia Carramusa; Abraham Avigdor; Stefano Volinia; Arthur Buchberg; Alex Mazo; Orit Kollet; Corey Largman; Carlo M Croce; Tatsuya Nakamura; Tsvee Lapidot; Eli Canaani
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

2.  PU.1 immortalizes hematopoietic progenitors in a GM-CSF-dependent manner.

Authors:  Isaac B Houston; Kelly J Huang; Serena R Jennings; Rodney P DeKoter
Journal:  Exp Hematol       Date:  2007-03       Impact factor: 3.084

3.  Identification of E74-like factor 1 (ELF1) as a transcriptional regulator of the Hox cofactor MEIS1.

Authors:  Ping Xiang; Chaoyu Lo; Bob Argiropoulos; C Benjamin Lai; Arefeh Rouhi; Suzan Imren; Xiaoyan Jiang; Dixie Mager; R Keith Humphries
Journal:  Exp Hematol       Date:  2010-06-23       Impact factor: 3.084

Review 4.  Cooperating gene mutations in acute myeloid leukemia: a review of the literature.

Authors:  A Renneville; C Roumier; V Biggio; O Nibourel; N Boissel; P Fenaux; C Preudhomme
Journal:  Leukemia       Date:  2008-02-21       Impact factor: 11.528

5.  HOXA9 modulates its oncogenic partner Meis1 to influence normal hematopoiesis.

Authors:  Yu-Long Hu; Steve Fong; Christina Ferrell; Corey Largman; Wei-Fang Shen
Journal:  Mol Cell Biol       Date:  2009-07-20       Impact factor: 4.272

6.  Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.

Authors:  Frank Rosenbauer; Katharina Wagner; Jeffery L Kutok; Hiromi Iwasaki; Michelle M Le Beau; Yutaka Okuno; Koichi Akashi; Steven Fiering; Daniel G Tenen
Journal:  Nat Genet       Date:  2004-05-16       Impact factor: 38.330

7.  The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.

Authors:  Rajani K Vangala; Marion S Heiss-Neumann; Janki S Rangatia; Sheo M Singh; Claudia Schoch; Daniel G Tenen; Wolfgang Hiddemann; Gerhard Behre
Journal:  Blood       Date:  2002-08-29       Impact factor: 22.113

8.  Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors.

Authors:  Stephen L Nutt; Donald Metcalf; Angela D'Amico; Matthew Polli; Li Wu
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

9.  Sustained PU.1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells.

Authors:  Philipp B Staber; Pu Zhang; Min Ye; Robert S Welner; César Nombela-Arrieta; Christian Bach; Marc Kerenyi; Boris A Bartholdy; Hong Zhang; Meritxell Alberich-Jordà; Sanghoon Lee; Henry Yang; Felicia Ng; Junyan Zhang; Mathias Leddin; Leslie E Silberstein; Gerald Hoefler; Stuart H Orkin; Berthold Göttgens; Frank Rosenbauer; Gang Huang; Daniel G Tenen
Journal:  Mol Cell       Date:  2013-02-08       Impact factor: 17.970

Review 10.  PU.1 and partners: regulation of haematopoietic stem cell fate in normal and malignant haematopoiesis.

Authors:  Pallavi Gupta; Gangenahalli U Gurudutta; Daman Saluja; Rajendra P Tripathi
Journal:  J Cell Mol Med       Date:  2009-04-06       Impact factor: 5.310

View more
  2 in total

Review 1.  Deregulation of the HOXA9/MEIS1 axis in acute leukemia.

Authors:  Cailin T Collins; Jay L Hess
Journal:  Curr Opin Hematol       Date:  2016-07       Impact factor: 3.284

2.  High expression of PU.1 is associated with Her-2 and shorter survival in patients with breast cancer.

Authors:  Jing Lin; Wei Liu; Tian Luan; Lili Yuan; Wei Jiang; Huilong Cai; Weiguang Yuan; Yuwen Wang; Qingyuan Zhang; Lihong Wang
Journal:  Oncol Lett       Date:  2017-10-18       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.